Droxidopa Market - Forecast(2023 - 2028)

Droxidopa Market Overview

The Droxidopa Market size is forecast to reach US$487.1 million by 2027, after growing at a CAGR of 7.8% during 2022-2027. Droxidopa is a medication widely used to treat symptoms of neurogenic orthostatic hypotension that increases the deficient supply of norepinephrine as well as dopamine in patients with neurogenic orthostatic hypotension in the youth population. It is mainly caused by dopamine beta-hydroxylase deficiency, non-diabetic autonomic neuropathy, and primary autonomic failure. Droxidopa crosses the blood brain barrier, to convert norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Droxidopa helps to improve orthostatic blood pressure and various related problems associated with lightheadedness, dizziness, blurred vision, and syncope through the increased heart rate and hypertension. According to World Health Organisation, around 1.28 billion adults aged 30-79 years have hypertension globally and are found mostly in low- and middle-income countries. Therefore, the growing rate of hypertension and related disease will boost the demand for the Droxidopa Market during the forecast period.

COVID-19 Impact

The Covid-19 pandemic has been a major challenge across the globe owing to directly affecting the manufacturer's supply chain and shutting down the production facilities to minimize the risk of virus spread. The major sectors such as pharmaceutical, construction, industrial, and others have been highly impacted. The COVID-19 pandemic has created a serious fault line in the supply chain across the globe for essential products like active pharmaceutical ingredients(API), masks, personal protection equipment (PPE), testing kits, drugs, and ventilators as most of the APIs are being produced by China and India. This results in the supply chain disturbance as trade got affected due to the pandemic. Also, due to the social distancing policy, most businesses got disturbed and people lost jobs. According to Franchise Organisation, around 32,700 franchised businesses are closed, and anticipated that 21,834 of these businesses are only temporarily closed and will re-open, while 10,875 businesses are closed permanently as of the end of August 2020. This has increased the number of people suffering from hypertension owing to an increase in stress levels but it was neglected by the people as the most focus was to treat the covid patient. As the pandemic affected the markets in each country, the strengths and weaknesses of the various sector in each country will shape future outcomes. The initiation taken by the government and private sector will help to recover the Droxidopa Market during the forecast period.

Report Coverage

The report: “Droxidopa Market Report – Forecast (2022-2027)”, by IndustryARC, covers an in-depth analysis of the following segments of the Droxidopa industry.

Key Takeaways

• The Asia Pacific is expected to register a CAGR of 8.8% during the forecast period (2022-2027). The increasing diseases like anemia, dizziness, dehydration, and syncope in Asian countries such as China, India, Japan, and South Korea are driving the market for droxidopa.
• Increasing research & development to treat symptomatic neurogenic orthostatic hypotension (nOH) caused by dopamine beta-hydroxylase deficiency and others will drive the Droxidopa Market.
• The growing working class and increasing stress levels resulting in increasing neurogenic orthostatic hypotension diseases will boost the Droxidopa Market by 2027

For More Details on This Report - Request for Sample

Droxidopa Market Segment Analysis – By Form

The capsule segments accounted for around 40% of the market share in 2021 and are estimated to grow at a significant CAGR during the forecast period. Capsules observed the nutrients present in a better way than the nutrients obtained from other forms. The drugs which are present in the capsules are considered to enter the bloodstream of people immediately. Capsules of droxidopa are widely used to treat neurogenic orthostatic hypotension mainly caused due to deficient supply of norepinephrine to give immediate relief to the patient. According to American Heart Association, during the first 24 weeks of pregnancy, there is a high risk of neurogenic orthostatic hypotension. Therefore, the use of droxidopa capsules for the treatment of neurogenic orthostatic hypotension will boost demand for the Droxidopa Market during the forecast period.

Droxidopa Market Segment Analysis - By Dosage

The droxidopa 300 Mg segment accounted for approximately 38% of the market share in 2021 and is estimated to grow at a significant CAGR during the forecast period. The droxidopa 300 Mg is widely used for the treatment of orthostatic dizziness, lightheadedness, or blackout feeling in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) mainly due to primary autonomic failure, multiple system atrophy, and others. According to World Health Organisation, iron deficiency anemia is the second leading cause of adolescent death and disability. Therefore, increasing iron deficiency among the youth population will increase the cases of neurogenic orthostatic hypotension (nOH), and in turn, will boost the need and demand for droxidopa 300 Mg during the forecast period.

Droxidopa Market Segment Analysis - By Geography

Asia Pacific region held the largest share in the Droxidopa Market in 2021 up to 34%, owing to the growing working class, and other related symptomatic diseases, in developing countries like China, India, Indonesia, and others. The major factor responsible for the growth of global droxidopa is neurogenic orthostatic hypotension which results in a fall in blood pressure, due to a deficiency of norepinephrine release from sympathetic nerve terminals. According to India Brand Equity Foundation, Information Technology(IT) is projected to increase by US$98.5 billion in 2022 owing to the top three Indian IT companies, TCS, Wipro, and Infosys, are expected to create jobs opportunity for around 1.05 lakh, due to the increasing demand for talent and skills in 2022. Also, the IT and business services market of India is estimated to reach US$19.93 billion by 2025. Therefore, the growing working class in the region results in various symptomatic diseases due to long sitting hours will boost the Droxidopa Market.

Droxidopa Market Drivers:

The rise in factors of Neurogenic orthostatic hypotension like Anemia, Dehydration, Endocrine problems, and others will drive the Droxidopa Market

The growth factor of neurogenic orthostatic hypotension like anemia, dehydration, endocrine problems, and others will drive the Droxidopa Market during the forecast period. According to US Centre for Disease Control and Prevention, 890,000 people have visited emergency departments with anemia as the primary diagnosis. According to World Health Organisation, the prevalence of anemia in women of reproductive age (aged 15-49) is more. Also, 614 million women and 280 million children globally are suffering from anemia as of April 2020. Thus, the rise in factors responsible for neurogenic orthostatic hypotension will boost the need and demand for droxidopa medicine, which in turn will help in the growth of the Droxidopa Market.

Droxidopa Market Challenges:

Adverse Effect of Droxidopa

Droxidopa is widely used to treat neurogenic orthostatic hypotension (low blood pressure). Excessive use of droxidopa may cause hypertension which is one of the major factors hindering the market growth. Also, droxidopa has minimal side effects which include headache, Bladder pain, dizziness, fainting, nervousness, pounding in the ears, heartbeat fluctuation, and others. Also, the lack of awareness of the droxidopa medication among a specific section of the population is hampering the market growth during the forecast period.

Global Droxidopa Industry Outlook

Technology launches, acquisitions, and R&D activities are key strategies adopted by players in the Droxidopa Market. Global droxidopa top 10 companies include

1. Piramal Enterprises Limited
2. Lupin Ltd
3. Clarochem Ireland Ltd
4. Estechpharma Co., Ltd.
5. Sun Pharmaceutical Industries Ltd.
6. JINLAN Pharm-Drugs Technology Co., Ltd.
7. Chongqing Shenghuaxi Pharm Co., Ltd.
8. Hikma Pharmaceuticals PLC
9. Chelsea Therapeutics International, Ltd.
10. Dainippon Sumitomo Pharma

Recent Developments

• In September 2021, Lupin Limited has launched Droxidopa Capsules, 100 mg, 200 mg, and 300 mg indicated for the treatment of orthostatic dizziness, lightheadedness, or the 'feeling that you are about to black out' in adult patients with symptomatic neurogenic orthostatic hypotension (nOH)
• In March 2021, Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announced that it has received FDA approval for droxidopa and launched Droxidopa Capsules, the generic equivalent to Northera® of 100mg, 200mg, and 300mg doses through its US affiliate, Hikma Pharmaceuticals USA Inc.
• In February 2021, Global pharma major Lupin Limited (Lupin), announced receiving approval for its Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, from the United States Food and Drug Administration, to market a generic equivalent of Northera® Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA Ltd. The product will be manufactured at Lupin’s facility in Nagpur, India.

Relevant Reports

Ampicillin Market Analysis - Forecast(2022 - 2027)

Report Code: CMR 0246

Acid Market - Forecast(2022 - 2027)

Report Code: CMR 0255

Antiemetic Drugs Market - Forecast(2022 - 2027)

Report Code: HCR 0141

For more Chemicals and Materials Market reports, please click here